Fecal Microbiota Therapy for Recurrent<i>Clostridium difficile</i>Infection in HIV-Infected Persons
Authors: Latesha Elopre, Martin Rodriguez
Journal: Annals of Internal Medicine (2013)

Letters21 May 2013Fecal Microbiota Therapy for Recurrent Clostridium difficile Infection in HIV-Infected PersonsLatesha Elopre, MD and Martin Rodriguez, MDLatesha Elopre, MDFrom University of Alabama at Birmingham, Birmingham, Alabama. and Martin Rodriguez, MDFrom University of Alabama at Birmingham, Birmingham, Alabama.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-10-201305210-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Recurrent Clostridium difficile infection is common and difficult to manage. It returns in approximately 20% to 30% of cases after a first episode and more frequently after recurrent episodes (1). Because of the high rate of recurrence, many treatment alternatives have been proposed, especially metronidazole or vancomycin (including pulsed or tapered vancomycin); however, these therapies are often unsuccessful (1, 2). Disrupted fecal microbiota from previous antibiotics play a major role in recurrent C. difficile infection, and fecal microbiota therapy works by restoring the recipient's natural microbiota (1). The procedure includes testing the donor for infections that could be transmitted ...References1. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994-1002. [PMID: 22002980] CrossrefMedlineGoogle Scholar2. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580-5. [PMID: 12594638] CrossrefMedlineGoogle Scholar3. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-15. [PMID: 23323867] CrossrefMedlineGoogle Scholar4. Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14:161-5. [PMID: 23121625] CrossrefMedlineGoogle Scholar5. Sivapalasingam S, Blaser MJ. Bacterial diarrhea in HIV-infected patients: why Clostridium difficile, and why now? [Editorial]. Clin Infect Dis. 2005;41:1628-30. [PMID: 16267736] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Alabama at Birmingham, Birmingham, Alabama.Disclosures: Dr. Rodriguez: Grants/grants pending: Merck. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBritish HIV Association guidelines on the management of opportunistic infection in people living with HIV: the clinical management of gastrointestinal opportunistic infections 2020South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guidelineRegulation of Gut Microbiota on Immune Reconstitution in Patients With Acquired Immunodeficiency SyndromeTherapeutic avenues for restoring the gut microbiome in HIV infectionTreating From the Inside Out: Relevance of Fecal Microbiota Transplantation to Counteract Gut Damage in GVHD and HIV InfectionImmunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIVHIV and the Gut Microbiota: Composition, Consequences, and Avenues for AmeliorationClostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and PreventionClinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised PatientsTrasplante de microbiota fecal en el tratamiento de colitis grave complicada por C. difficile en un paciente con síndrome de inmunodeficiencia adquiridaFecal microbiota transplantation for severe complicated C. difficile colitis in a patient with acquired immunodeficiency syndromeA Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised PatientsIntestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota TransplantationLimited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individualsFecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patientsLoss of Vancomycin-Resistant Enterococcus Fecal Dominance in an Organ Transplant Patient With Clostridium difficile Colitis After Fecal Microbiota TransplantFecal microbiota transplantation as novel therapy in gastroenterology: A systematic reviewRapidly expanding knowledge on the role of the gut microbiome in health and disease 21 May 2013Volume 158, Issue 10Page: 779-780KeywordsAIDSAntibioticsDiarrheaHighly active antiretroviral therapyStem cellsToxinsType 2 diabetesVancomycinViral load ePublished: 21 May 2013 Issue Published: 21 May 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...